Connect Biopharma (ADR) (CNTB)
Develops rademikibart for asthma and COPD outside Greater China.
Something off on this page? Send us feedback.
Develops rademikibart for asthma and COPD while other programs remain paused. Simcere holds Greater China rights, while Connect retains rights elsewhere.
Develops rademikibart, an anti-IL-4Rα antibody, as its lead candidate for asthma and COPD. The company concentrates its non-China effort on clinical development after pausing preclinical and discovery programs. It previously pursued a broader T-cell-inflammation pipeline.
Operations reflect San Diego headquarters and historical US–China development roots. Simcere holds exclusive Greater China rights to develop, manufacture and commercialize rademikibart, while Connect retains rights in the rest of the world. This arrangement divides development and commercialization responsibilities by region.
Near-term progress depends on pending Phase 2 Seabreeze STAT readouts in asthma and COPD. The drug candidate remains the company’s central program.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 14, 2026 | Canaccord Genuity | Target | Target: $6 | Target: $7 |
| Jul 9, 2026 | Oppenheimer | Initiate | Rating: —Target: — | Target: $8 |
| Jun 26, 2026 | Piper Sandler | Initiate | Rating: —Target: $1.50 | Target: $7 |
| Jun 18, 2026 | H.C. Wainwright | Target | Target: — | Target: $7 |
| May 26, 2026 | Canaccord Genuity | Target | Target: — | Target: $6 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $31.5M · Total debt $596.0K · Total assets $43.5M · Shareholders' equity $26.9M
- Revenue
- $2.9M
- Operating income
- −$37.2M
- Net income
- −$36.7M
No dividends on record.
| Institutions | 22.09% | 13.91M ADS | |
|---|---|---|---|
| 57 holders · as of Jun 30, 2026 | |||
| Insiders | 37.95% | 23.90M ADS | |
| 9 holders · as of Jul 1, 2026 | |||
| Strategic holders | 36.74% | 23.14M ADS | |
| 3 holders · as of Apr 14, 2026 | |||
| Other | 3.22% | 2.03M ADS | |
| remainder | |||
62.97M ADS as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Panacea Innovation LimitedStrategic | 22.15% | 13.95M | filed Jul 21, 2025 |
James HuangInsiderdirector | 21.14% | 13.31M ordinary | filed Jun 2, 2026 |
Wubin PanInsider | 9.71% | 6.12M | filed Feb 25, 2022 |
BioFortune IncStrategic | 9.51% | 5.99M | filed Apr 14, 2026 |
Ikarian Capital, LLCInstitution | 7.21% | 4.54M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 29, 2026 | James Huang | director | +150,000 | $2.48 |
| Mar 31, 2026 | James Huang | director | +1,160,000 | $3.45 |
- Regeneron
Dupixent co-developer in asthma and eosinophilic COPD maintenance
- Sanofi (ADR)
Dupixent co-developer in asthma and eosinophilic COPD maintenance
- GSK (ADR)
Nucala spans severe asthma and eosinophilic COPD maintenance
- AstraZeneca (ADR)
Tezspire and Fasenra cover severe asthma biologics
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Connect Biopharma (ADR) | $1.13 | −7.41% | $76.5M | — | — | 26.0 | +5,624.9% |
| Regeneron | $797.99 | −0.74% | $82.82B | 19.9 | 13.2 | 5.3 | +16.7% |
| Sanofi (ADR) | $41.50 | −2.39% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| GSK (ADR) | $49.73 | −1.96% | $101.62B | 16.1 | 9.2 | 2.3 | +5.3% |
| AstraZeneca (ADR) | $163.74 | −2.75% | $261.12B | 25.3 | 15.4 | 4.3 | +6.4% |
| Median | 22.6 | 13.2 | 3.3 | +8.8% |